A pancreatic cancer organoid-in-matrix platform shows distinct sensitivities to T cell killing

Anton Lahusen1, Jierui Cai1, Reinhold Schirmbeck1

  • 1Department of Internal Medicine I, Gastroenterology, Endocrinology, Nephrology, Nutrition and Metabolism, Ulm University Hospital, Albert Einstein Allee 23, 89081, Ulm, Germany.

Scientific Reports
|April 23, 2024
PubMed

Insights

A new InterOMaX model system enhances organoid cultures to study pancreatic cancer cell interactions within the tumor microenvironment, revealing T cell resistance mechanisms.

Area of Science:

  • Oncology
  • Cancer Biology
  • Immunology

Background:

  • Pancreatic ductal adenocarcinoma (PDAC) exhibits poor treatment response due to tumor heterogeneity and an immunosuppressive tumor microenvironment (TME).
  • Existing organoid models require improved culture conditions to accurately mimic the TME for studying cellular crosstalk.
  • There is a need for advanced models to investigate the complex interactions within the PDAC TME.

Purpose of the Study:

  • To introduce and validate the INTERaction with Organoid-in-MatriX (InterOMaX) model system.
  • To investigate matrix-dependent cellular crosstalk in PDAC.
  • To uncover molecular mechanisms of T cell responses and resistance in PDAC.

Main Methods:

  • Developed a 3D co-culture platform (InterOMaX) using a standardized agarose microwell chip array.
  • Incorporated customizable matrices for homogenous organoid-in-matrix positioning of cancer cells.
  • Co-cultured murine KPC PDAC cells and patient-derived organoids (PDOs) with T cells and stromal cells.

Main Results:

  • The InterOMaX system enables investigation of T cell responses to PDAC cells and PDOs.
  • Identified distinct PDAC cell populations with varying sensitivity to T cell killing, corroborated in vivo.
  • Facilitated the identification and validation of gene candidates associated with T cell resistance.

Conclusions:

  • The InterOMaX platform provides a robust model for studying TME interactions in PDAC.
  • This system aids in understanding cancer cell-intrinsic resistance phenotypes to T cell-mediated killing.
  • The InterOMaX model sets the stage for developing improved therapeutic strategies for PDAC.

Related Concept Videos